NEW YORK – Adaptive Biotechnologies and AstraZeneca announced Monday a collaboration to use Adaptive's ImmunoSeq T-Map technology to analyze immune response to cancer antigens across AstraZeneca's oncology portfolio.
Under the terms of the deal, AstraZeneca will provide biological samples from patients with cancer. Adaptive will sequence these samples and deliver T cell receptor and antigen mapping data, which may inform signatures of immune response or resistance to cancer therapies.